多替阿巴拉米片是什么药物？

It was approved for marketing by FDA on August 27, 2014. Subsequently, on January 22, 2018, GlaxoSmithKline (GSK) announced that its single-pill compound preparation centered on the new generation integrase inhibitor dolutegravir (DTG) for the treatment of HIV was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. Dolutegra abalamib tablets have been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment for newly diagnosed AIDS patients. Today let’s learn about what kind of drug is Doteabalamid Tablets?

Inbec is a treatment plan with DTG, an integrase inhibitor, as the core drug, and two core drugs, abacavir and lamivudine. It is made into a single-tablet treatment and promoted, making the core drug a great improvement in HAART treatment. Dolutea Abalamide Tablets are suitable for adults and adolescents over 12 years old and weighing not less than 40 kg. Since the ingredients in Dolute Abalamib Tablets may cause hypersensitivity reactions, regardless of the patient's race, before starting treatment with abacavir-containing products, they should be screened for HLA-B*5701 alleles. The recommended dosage of dolutegra tablets is one tablet, once daily. Adults or adolescents whose weight is less than 40kg should not be given Dolutegra, because Dolutegra is a fixed-dose tablet and the dose cannot be reduced. Reducing the dose without authorization may result in the inefficiency of the drug. 

In 2018, GSK announced the launch of integrase DTG (Tervica) in China. This therapeutic agent has the advantages of small drug dosage, low resistance to drug resistance, and low probability of drug side effects. Dolutegravir tablets are based on DTG, an integrase inhibitor, as the core drug, and are combined with a treatment plan of two backbone drugs, abacavir and lamivudine, and are made into a single-tablet treatment for promotion, making the core drug a great progress in HAART treatment. In addition, this treatment agent can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work. 

The above is the content of the drug introduction, I hope it can help you!